Karyopharm Therapeutics (KPTI) Common Equity (2012 - 2026)

Karyopharm Therapeutics (KPTI) has reported Common Equity for 15 consecutive years, with -$330.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Common Equity fell 38.19% year-over-year to -$330.2 million; the trailing twelve-month figure through Jun 2026 stood at -$330.2 million (down 38.19% YoY), and the FY2025 full-year result was -$292.9 million, down 57.47% from the prior year.
• Common Equity eased to -$330.2 million in Q2 2026 per KPTI's latest filing, from -$292.9 million in the prior quarter.
• Across five years, Common Equity topped out at -$16.7 million in Q4 2022 and bottomed at -$330.2 million in Q2 2026.
• Historically, Common Equity has averaged -$158.4 million across 5 years, with a median of -$140.3 million in 2022.
• The sharpest annual moves came in 2022 and 2023: Common Equity soared 79.09% in 2022, then sank 717.76% in 2023.
• Over 5 years, Common Equity stood at -$16.7 million in 2022, then tumbled by 717.76% to -$136.2 million in 2023, then sank by 36.57% to -$186.0 million in 2024, then plunged by 57.47% to -$292.9 million in 2025, then dropped by 12.71% to -$330.2 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered -$330.2 million, -$292.9 million, and -$269.3 million for Q2 2026, Q4 2025, and Q3 2025 respectively.